Basilea sees another ceftobiprole rejection, isavuconazole delay

Swiss biotech Basilea Pharmaceutica saw its shares decline Friday after the European Committee for Medicinal Products for Human Use confirmed its previous negative opinion on the marketing authorization application for ceftobiprole to treat complicated skin and soft tissue infections. The news comes as Basilea's Japanese partner Astellas Pharma said it was expanding a late-stage trial of the antifungal isavuconazole, delaying the release of data up to 18 months. For ceftobiprole, the CHMP...